Pain Management

The Pharmacy Times® Pain Management resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, among other items that pharmacists will find valuable.

What can we help you find?
[[thumbnail_alt_text]]
Investigators found that approximately 36% of the patients studied received a dosage strength of 250 mg of morphine over a 5-day period, above the CDC’s threshold for risky opioid prescribing.
 
[[thumbnail_alt_text]]
In the United States, it is estimated that 34 million school hours and $45 billion are lost each year to unplanned dental care.
[[thumbnail_alt_text]]
New online training program is being deployed in response to data indicating a surge in opioid-related overdoses during the COVID-19 pandemic.
[[thumbnail_alt_text]]
Olicerdine is indicated for patients with severe pain who require an intravenous opioid when alternative treatments prove inadequate. 
 
[[thumbnail_alt_text]]
The Department of Health and Human Services awarded $101 million, mostly to rural communities, to fight the opioid epidemic.
[[thumbnail_alt_text]]
With a growing number of products containing cannabidiol and kratom available in the marketplace, many pharmacists and pharmacy students are increasingly being asked to discuss the use of these products.
[[thumbnail_alt_text]]
Perhaps no other health care worker has been exposed to the opioid epidemic more frequently than pharmacy technicians and pharmacists.
[[thumbnail_alt_text]]
In a recent statement, the FDA provided some guidelines for health care professionals when prescribing or renewing an opioid analgesic or medicine to treat opioid use disorder.
[[thumbnail_alt_text]]
The FDA released a recent statement explaining that it is now recommending all pharmacists discuss naloxone with patients when prescribing opioid pain relievers or medicines to treat opioid use disorder (OUD).
[[thumbnail_alt_text]]
The results of a level 1 trauma center study have shown that ibuprofen injection (Caldolor, Cumberland Pharmaceuticals) significantly reduces the quantity of opioids required to manage pain after a traumatic injury with fracture.
[[thumbnail_alt_text]]
The medication is indicated for the relief of mild to moderate pain caused by acute musculoskeletal disorders.
[[thumbnail_alt_text]]
With medicinal cannabis research in its infancy, many health care providers are unsure how to provide accurate counseling and appropriate treatment to their patients.